mTOR Signaling Reshapes Bile Acid Profiles and Drives Metabolic Liver Disease
New research links mTORC1-TFEB/TFE3 signaling to bile acid remodeling, revealing how nutrient sensing shapes fatty liver disease risk.
Summary
Scientists have discovered that mTORC1, the master nutrient-sensing pathway central to aging and longevity, orchestrates a previously unrecognized remodeling of bile acid metabolism in the liver. When mTORC1 activity shifts — as it does during dietary changes, metabolic stress, or aging — it alters the balance of bile acid species through transcription factors TFEB and TFE3. These shifts in bile acid composition appear tied to the progression or improvement of metabolic dysfunction-associated steatotic liver disease (MASLD), the most common chronic liver condition globally. Notably, protein restriction, which dampens mTORC1 activity, reshaped bile acid profiles in mice and correlated with better metabolic outcomes in human MASLD patients. Blocking TFE3 or treating with rapamycin reversed some of these changes, suggesting bile acid homeostasis is a meaningful lever in nutrient-sensing biology.
Detailed Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver condition and a major driver of liver failure and metabolic disease as people age. Understanding how the liver adapts to nutrient signals is therefore a central question in longevity science.
This study, published in Science Advances, focuses on mTORC1 — the mechanistic target of rapamycin complex 1 — a pivotal pathway that senses nutrients, hormones, and energy status to govern metabolism. The researchers investigated how mTORC1 and its downstream transcription factors TFEB and TFE3 regulate bile acid (BA) metabolism during hepatic adaptation to metabolic stress.
The team found that altered mTORC1-TFEB/TFE3 signaling is associated with coordinated remodeling of bile acid synthesis and transformation. Specifically, changes in the liver enzymes Cyp2c70 and Cyp8b1, combined with altered cholesterol trafficking, were associated with shifts toward non-12-OH or 12-OH bile acid species, with the direction of the shift depending on the mTORC1 signaling state. According to the abstract, these effects were attenuated or reversed by Tfe3 deletion or rapamycin treatment.
In translational experiments, protein restriction — a well-established mTORC1 inhibitor and longevity-associated dietary intervention — similarly reshaped bile acid profiles in mice and correlated with improved metabolic outcomes in human MASLD patients, bridging preclinical and clinical evidence.
These findings position bile acid homeostasis as an integral component of the metabolic adaptations linked to mTOR signaling, not merely a downstream byproduct. For longevity-focused practitioners, this suggests that some benefits of protein restriction and mTOR inhibition may partly operate through bile acid remodeling — a mechanism previously underappreciated in the context of healthspan extension and liver metabolic health.
Caveats include reliance on the abstract alone and lack of detail on patient cohort size and the directionality of causation.
Key Findings
- mTORC1-TFEB/TFE3 signaling controls bile acid composition in the liver, shifting balance between 12-OH and non-12-OH bile acid species.
- Liver enzymes Cyp2c70 and Cyp8b1 and altered cholesterol trafficking mediate the bile acid shifts driven by mTORC1 activity.
- Rapamycin treatment or Tfe3 gene deletion reversed mTORC1-driven bile acid remodeling in mouse models.
- Protein restriction, which suppresses mTORC1, reshaped bile acid profiles in mice and improved metabolic outcomes in human MASLD patients.
- Bile acid homeostasis is newly identified as an integral output of mTOR nutrient-sensing, with direct implications for fatty liver disease.
Methodology
The study combined mouse genetic models (including Tfe3 knockout) with pharmacological mTOR inhibition using rapamycin, lipidomic and metabolomic profiling of bile acid species, and translational analysis of human MASLD patients undergoing protein restriction. Multiple institutions across Europe and North America contributed data, suggesting a large collaborative dataset.
Study Limitations
This summary is based on the abstract only, as the full paper was not accessible. The mechanistic directionality — whether bile acid shifts cause metabolic improvement or are simply correlated — is not fully resolvable from the abstract. The size and design of the human MASLD patient cohort are not described, limiting assessment of clinical generalizability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: